Agile Therapeutics, Inc. reaffirmed revenue guidance for the Full Year 2023. For the year, the company reaffirmed Net Revenue of At Least $25 Million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.375 USD | -9.57% | -7.36% | -80.77% |
03-28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
03-28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
1st Jan change | Capi. | |
---|---|---|
-80.77% | 2.84M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023